Protagonist Therapeutics (PTGX) Reports Q4 Loss of $0.15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Protagonist Therapeutics (PTGX) PT Trimmed to $42 at BMO Capital, But Sees Catalyst-Rich 2018
March 8, 2018 5:47 AM ESTBMO Capital analyst M. Ian Somaiya lowered his price target on Protagonist Therapeutics (NASDAQ: PTGX) to $42.00 (from $44.00) while maintaining an Outperform rating.
Somaiya notes Protagonists low risk pipeline is quickly maturing with an interim analysis (futility) of the Phase 2b... More
